Technical Data
045188
(R)-Roscovitine (6-Benzylamino-2-(R)-9-isopropylpurine)
1mg
Biochemicals Storage: 4C/-20CShipping: Blue Ice
Potent and selective inhibitor of CDKs. More potent than olomoucine. Inhibits CDK1/cyclin B kinase (IC50 = 450 nM), CDK2 (IC50 = 700 nM) and CDK5/p35 (IC50 = 160 nM). Inhibits M phase promoting factor (MPF) kinase activity. Arrests human fibroblasts in G1 phase. Antitumor compound. Activates the mitogen-activated protein kinase pathway. Targets both the p53 and NF-kappaB pathways. Has effects on calcium channel gating. Prevents DNA damage-induced cyclin A1 upregulation. Apoptosis inducer. As CYC202 in phase I clinical trials. Reviews.

Storage and Stability:
Short-term Storage: +4C
Long-term Storage: -20C
Stable for at least 2 years after receipt when stored at -20C.

CAS Number:
186692-46-6

Molecular Formula:
C19H26N6O

Molecular Weight:
354.5
Purity: >98% (NMR)

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference:
Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosis: B. Rudolph, et al.; EMBO J. 15, 3065 (1996)
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5: L. Meijer, et al.; Eur. J. Biochem. 243, 527 (1997)
Chemical inhibitors of cyclin-dependent kinases: L. Meijer and S.H. Kim; Meth. Enzymol. 283, 113 (1997)
Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds: L. Havlicek, et al.; J. Med. Chem. 40, 408 (1997)
Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist: J.W. Pippin, et al.; J. Clin. Invest. 100, 2512 (1997)
The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity: F. Alessi, et al.; Exp. Cell Res. 245, 8 (1998)
The specificities of protein kinase inhibitors: an update: J. Bain, et al.; Biochem. J. 371, 199 (2003)
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine): S.J. McClue, et al.; Int. J. Cancer 102, 463 (2002)
The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway: S.R. Whittaker, et al.; Cancer Res. 64, 262 (2004)
R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy: A. Dey, et al.; Cell Death Differ. 15, 263 (2008)
The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1: R. Duffin, et al.; FEBS Lett. 583, 2540 (2009)
(R)-roscovitine prolongs the mean open time of unitary N-type calcium channel currents: N.R. DeStefino, et al.; Neuroscience 167, 838 (2010)
R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair: M. Federico, et al.; Mol. Cancer 9,208 (2010)
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies: C. Le Tourneau, et al.; Eur. J. Cancer 46, 3243 (2010)
Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons: E.A. Monaco, 3rd, et al.; Biochem. Pharmacol. 67, 1947 (2004)
Roscovitine targets, protein kinases and pyridoxal kinase: S. Bach, et al.; J. Biol. Chem. 280, 31208 (2005)
The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction: S. Cho & S.D. Meriney; Eur. J. Neurosci. 23, 3200 (2006)
Roscovitine differentially affects CaV2 and Kv channels by binding to the open state: Z. Buraei, et al.; Neuropharmacology 52, 883 (2007)
Cyclin-dependent kinase inhibitors as anticancer drugs: V. Krystof & S. Uldrijan; Curr. Drug Targets 11, 291 (2010)
Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells: O.P. Mgbonyebi, et al.; Cancer Res. 59, 1903 (1999)


Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.